Form 4: Arcutis CFO Sells Shares for Tax Obligations

Arcutis Biotherapeutics' SVP Chief Financial Officer, Latha Vairavan, sold 89 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Latha Vairavan, SVP Chief Financial Officer of Arcutis Biotherapeutics, Inc. (ARQT), sold 89 shares of common stock.
• The sale occurred on August 4, 2025, at a weighted average price of $14.3266 per share.
• The shares were sold in multiple transactions ranging from $13.98 to $14.67.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• Following this transaction, Latha Vairavan beneficially owns 65,015 shares of Arcutis Biotherapeutics common stock.
• The transaction was executed under a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, non-discretionary transaction by an insider to cover tax obligations upon RSU vesting, which is a common occurrence and does not typically indicate a change in management's outlook on the company.

Positives

• The sale was explicitly for tax withholding obligations, indicating it was not a discretionary sale based on a negative outlook for the company.
• The transaction was conducted under a Rule 10b5-1 plan, which suggests a pre-planned, non-discretionary sale.

Negatives

• A small reduction in insider ownership, though for a specific, non-discretionary reason.

Future Outlook

NA

Industry Context

This is a routine insider transaction (sell-to-cover) common across all industries, including biotechnology. It does not reflect specific industry trends.

Comparison to Industry Standards

• This is a standard 'sell to cover' transaction for tax obligations, common for executives receiving equity compensation across all industries. It is not comparable to company performance metrics or project results.

Stakeholder Impact

• Minimal impact on shareholders as it's a small, non-discretionary sale for tax purposes.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by a company executive to satisfy tax obligations related to RSU vesting. Such transactions are common and typically do not reflect a change in the executive's confidence in the company's future prospects. The small number of shares sold (89) relative to the executive's remaining holdings (65,015) further supports this. Therefore, this filing alone does not provide a basis for a change in investment recommendation; a 'hold' stance is maintained, pending more substantive company news or financial results.

Keywords

Arcutis Biotherapeutics, ARQT, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, RSU, Latha Vairavan, CFO, Biotechnology, Pharmaceuticals